TRDA
Entrada Therapeutics, Inc.
Biotechnology · Healthcare · United States
4.54
close · 2026-10-30
value
48
cheaper than peers48
quality
12
stronger fundamentals12
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | 76.0% | 100 |
| earnings yield, 1 year ago | 37.0% | 99 |
| price to book | 0.70× | 91 |
| earnings yield, 2 years ago | -4.4% | 79 |
| cash flow yield, 1 year ago | -25.3% | 28 |
| price to sales | 37.68× | 27 |
| earnings yield, 3 years ago | -66.6% | 26 |
| cash flow yield, 3 years ago | -54.7% | 17 |
| earnings yield, latest year | -76.5% | 13 |
| cash flow yield, latest year | -73.4% | 13 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 20.8% | 48 |
| return on equity | -54.1% | 45 |
| revenue growth | -53.9% | 18 |
| operating margin | -5007.0% | 4 |
4 of 4 measures available
Facts
| market cap | $177M |
| free cash flow | -$77.7M |
| employees | 152 |
| first trade | 2021-10-29 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.47 | 1.68 | -0.20 | -3.02 |
| free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M |
| net income | -$143.8M | $65.6M | -$6.7M | -$94.6M |
| revenue | $25.4M | $210.8M | $129.0M | $0 |